// App-Quantinova.ai

BSH19‐EP‐024 : Successful treatment of primary cutaneous diffuse large B cell lymphoma leg type with single agent venetoclax

Researchers

Presenter

  • C.S. Trethewey

Principal Investigators

  • H.S. Walter

  • R. Jackson

  • M.J. Ahearne

  • S. Jayne

  • S.D. Wagner

  • G. Saldanha

  • M.J.S. Dyer

Medical Centers

  • Leicester Cancer Research Centre,University of Leicester,Leicester,United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • Interferon regulatory factor 4

  • Neurogenic locus notch homolog protein 2

  • AT-rich interactive domain 1A

  • B-cell lymphoma 2

  • B-cell lymphoma 6

  • B-lymphocyte antigen CD20

  • Breakpoint Cluster Region

  • Bruton tyrosine kinase

  • Paired box 5

  • Cluster of differentiation 79A

  • Proliferation marker protein Ki-67

  • Cyclin Dependent Kinase Inhibitor 2A

  • Retinoblastoma protein

  • Tumor protein p53

Drug/Treatment

  • Venetoclax

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved